Tepedino, Berezowski e Poppa Advogados

We are only able to display limited information for this firm. We display more complete information for all of the following firms:

Boasting considerable experience in high-value, high-stakes contentious matters, Tepedino, Berezowski e Poppa Advogados advises a range of clients across sectors such as financial services, real estate, construction, telecoms and healthcare on corporate and commercial litigation. Co-head Bruno Poppa is turned to by a host of clients – including banks and investment funds – for his expertise in corporate, commercial and civil liability disputes. Also at the helm of the practice, Aluisio Berezowski is proficient in civil and commercial litigation, while José Eduardo Tavanti Junior is skilled in commercial, corporate, contractual and public law cases. Meanwhile, Luiz Guilherme Martins Costa specialises in complex corporate and contractual disputes, with particular emphasis on minority shareholder-related matters; Rodolfo Fontana advises on restructuring and insolvency matters; and André Yukio Lacerda handles both corporate and civil litigation.
Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘Tepedino, Berezowski e Poppa Advogados is, without a doubt, my first call when it comes to litigation cases. The firm combines a very high technical level with exceptional customer service. The team is extremely competent, accessible and has a very accurate understanding of the needs of the cases and the objectives of the client, always acting with strategy, clarity and agility.'

  • 'In addition to the technical quality, what sets the firm apart in the market is its practical and balanced approach: they can deliver sophisticated work, with attention to detail and in-depth legal knowledge, but without losing sight of the business context and the cost-benefit ratio, which is increasingly rare.'

Key clients

  • Banco BTG S/A
  • Cogna Educação S/A

Work highlights

Secured a favourable ruling for PSS Kyros in a R$10bn litigation funding case against Novonor.